Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03826836 Not yet recruiting - Heart Failure Clinical Trials

Mind Our Heart Study

Start date: January 2019
Phase: N/A
Study type: Interventional

Patients with atherosclerotic cardiovascular disease (i.e. peripheral artery disease, ischemic heart failure, myocardial infarction) are randomised to (1) treatment as usual (i.e. best medical care) or (2) treatment as usual (i.e. best medical care) in combination with an eight-week mindfulness-based stress reduction programme.

NCT ID: NCT03775993 Not yet recruiting - Heart Failure Clinical Trials

Treatment of GHD Associated With CHF

Start date: March 1, 2019
Phase: Phase 3
Study type: Interventional

Aim of the current study is to assess the cardiovascular effects of GH replacement therapy in patients with coexisting GHD and CHF

NCT ID: NCT03771729 Not yet recruiting - CKD Clinical Trials

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease(CKD)Patients With Heart Failure

Start date: December 30, 2018
Phase: Early Phase 1
Study type: Interventional

This paper will mainly present the renal results from a clinical study aimed to observe the effect of sacubitril/valsartan in advanced chronic kedney disease patients with heart failure.All patients will receive LCZ696.The results will be compared before and after treatment.

NCT ID: NCT03769272 Not yet recruiting - Heart Failure Clinical Trials

Optimal Left Ventricular Lead Positioning During Cardiac Resynchronisation Therapy; Comparison of Two Methods of Targeting

Start date: August 1, 2019
Phase:
Study type: Observational

Cardiac Resynchronisation Therapy (CRT) is a well-known treatment for patients with heart failure. It is a special pacemaker that consists of three pacing wires, which are implanted in the right upper and bottom chambers of the heart and via a vein on the surface of the main pumping chamber (left bottom chamber). CRT helps by improving co- ordination between the top and the bottom chambers of the heart. By stimulating the heart from the left and right bottom chambers, co-ordination can be restored and heart function as well as symptoms improve. It is known that up to 30-40% of patients of patients undergoing CRT pacemaker implantation do not attain any benefit. Given the inherent risks and costs of pacemaker implantation and maintenance, a reduction in the rate of CRT "non-responders" is an important goal. It has been suggested that presence of scar tissue in the heart and suboptimal placement of the pacing wire on the top of the main pumping chamber can explain this poor response. The best place to position the pacing wire on the surface of the main pumping chamber is the area that contracts last and it can be identified using ultrasound scan of the heart. Unfortunately, ultrasound is not always possible to help identifying the best area and only a minority of hospitals are able to use this method. Therefore we aim to investigate alternative ways of positioning the pacing wire in the best possible area of the main pumping heart chamber. Investigators propose to measure electrical signals as an alternative and more effective way in positioning the wire in the most effective area. Investigators aim to look at the relationship between the best area identified by ultrasound scan and by electrical signals and also use electrical signals to avoid areas of scar.

NCT ID: NCT03759405 Not yet recruiting - Clinical trials for Chronic Heart Failure

IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure

IDCVTCHF
Start date: December 31, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Based on the safety evaluation of primates, the best cell transplantation scheme was integrated. One patient with CHF caused by coronary heart disease, one patient with CHF caused by dilatation and one patient with CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation. The safety evaluation of human body was completed and combined with subjective and objective indexes respectively. Structural and functional indicators were used to evaluate the therapeutic effect of cell transplantation. The results of animal experiments confirmed the safety and effectiveness of intravenous myocardial cell transplantation, and clarified its possible mechanism.

NCT ID: NCT03751748 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Flow Regulation by Opening the Septum in Patients With Heart Failure Trial

FROST-HF
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

To investigate the safety and efficacy of a novel atrial flow regulator (AFR) device in patients with heart failure and preserved ejection fraction.

NCT ID: NCT03727282 Not yet recruiting - Heart Failure Clinical Trials

Left Ventricular Volume Index in the Adjustment of Initial Dose of Dobutamine in Heart Failure and Cardiogenic Shock

Start date: January 2, 2019
Phase: N/A
Study type: Interventional

Recent studies have suggested that the use of left ventricular ejection volume index calculation may aid in the hemodynamic management of critically ill patients. However, a prospective and randomized comparison in patients with heart failure for inotropic dose adjustment has not been described. The objective of this study was to evaluate the efficacy and safety of ejection volume index versus liberal strategy in adjusting dobutamine dose in patients with heart failure and low cardiac output. Methodology: A unicentric, randomized and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, dobutamine dose, complications) of patients will be analyzed for safety and effectiveness. Expected results: The use of ejection volume index is not inferior to the liberal strategy in the initial adjustment of the dose of dobutamine in patients with heart failure.

NCT ID: NCT03681379 Not yet recruiting - Acute Heart Failure Clinical Trials

Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units

PALMAréa
Start date: October 1, 2018
Phase:
Study type: Observational

To describe pharmacokinetics of levosimendan in neonates and children supported or not with extracorporeal circulation devices (ECMO, CRRT)

NCT ID: NCT03634189 Not yet recruiting - Heart Failure Clinical Trials

Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C

CAPITAL-AC
Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

Cannabidiol in heart failure

NCT ID: NCT03613064 Not yet recruiting - Clinical trials for Coronary Artery Disease

Addressing Social Vulnerabilities in Cardiovascular Disease

Start date: January 2022
Phase: N/A
Study type: Interventional

The investigators will conduct a feasibility study of an enhanced transitional care intervention, that will: 1) automate identification and risk-stratification of patients with CHF and IHD with social vulnerabilities; 2) incorporate a new standardized social vulnerabilities screening tool into clinical care; 3) enable electronic referrals to community resources; and 4) add novel community-based interventions to the existing medically-oriented transitional care intervention that is the standard of care at the study hospital (Parkland Hospital in Dallas, Texas) and other hospitals nationwide.